In Vitro Test Supplier & Suppliers serving the Thailand market

Yes. The Thai FDA Herbal and Cosmetic divisions recognize data generated according to international standards such as OECD Guidelines for the Testing of Chemicals, ISO 10993, and validated alternative methods. Our study reports include complete raw data, chromatographic traces, standard curves, and method validation parameters tailored for Thai FDA dossier compilation.

We provide complete sample logistics guidance, including commercial invoices, non-hazardous chemical declarations, and biological material customs classification. Lyophilized powders, botanical crude extracts, or packaged finished products generally arrive at our Changsha laboratories within 3–5 business days from Bangkok.

Absolutely. Our "Potency Evaluation by Origin, Season, and Plant Part" service combines quantitative HPLC/GC active compound determination with enzymatic or cell-based response assays to demonstrate potency variations between harvests (e.g., Krabi vs. Chiang Rai herbs).

Screening assays (such as rapid DPPH, ABTS, or basic MTT cytotoxicity) are high-speed discovery tools used to rank compounds during formulation development. Regulatory studies (such as OECD 439 reconstructed skin models or OECD 471 Ames genotoxicity) require rigorous GLP protocol fidelity to submit for formal product registration. We perform both tiers.

We operate strictly under formal Non-Disclosure Agreements (NDAs) subject to bilateral corporate governance. All testing protocols, customer-supplied proprietary recipes, and resulting pharmacological assay data remain exclusively the intellectual property of our client.

Yes. As an integrated CRO & CDMO, once an active extract demonstrates superior in vitro potency, our process engineering team optimizes extraction yield, spray-drying parameters, and excipient stabilization to manufacture OEM active ingredients or finished dosage forms (capsules, tablets, liquids).